Toggle light / dark theme

Alector initiates Phase 1 clinical trial for treatment of Alzheimer’s

Alector, a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, has announced the initiation of the first-in-human Phase 1 trial of AL044. The study is investigating the safety profile, pharmacokinetics (PK), pharmacodynamics (PD) and target engagement of AL044 in healthy adults.

Longevity. Technology: Headquartered in South San Francisco, California, Alector is aiming to develop an unmatched pipeline of novel potential medicines based on insights into immunology, neurology and human genetics. The company’s therapeutic candidates are intended to harness the body’s innate power to heal itself, and Alector is pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases, and innate immuno-oncology.

Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered, and is developing, a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease.

Pain-Sensing Gut Neurons Protect Against Inflammation

Summary: Pain-sensing neurons in the put secrete substance P, a molecule that protects against gut inflammation and tissue damage by boosting specific microbes in the gut. In people with inflammatory bowel disease, the pain-sensing neurons are diminished and there are significant disruptions in pain-signaling genes.

Source: Weill Cornell University.

Neurons that sense pain protect the gut from inflammation and associated tissue damage by regulating the microbial community living in the intestines, according to a study from researchers at Weill Cornell Medicine.

Elon Musk says he’s selling Perfume to gather cash for Twitter buyout

With a fresh comment, Elon Musk, the brains behind Tesla and SpaceX, has ignited Twitter once again. “Please purchase my perfume, so I can buy Twitter,” reads his most recent tweet. For those who are unaware, Elon Musk agreed to buy the social networking site Twitter in April 2022.

Twitter said in October 2022 that it had spoken with Elon Musk and that he had verified his willingness to pay the $44 billion sum in question. Musk now plans to make some money by offering perfume for sale online.

In the beginning, Musk bought a 9.2 percent share on Twitter. Musk, however, made the decision to fully acquire Twitter owing to several differences and a desire to promote “Free Speech” on the social networking platform. In April 2022, a settlement was reached between the two sides, and $54.20 per share in cash was agreed upon.

The Cerebellum Has a Function We Didn’t Even Know About, New Research Reveals

Given the complexity of the human body, it’s no surprise that we’re still making new discoveries about the different parts we’re made up of – and scientists have just made a new discovery about the cerebellum at the back of the brain.

Already known as being important for properly controlling our movements, it now appears that this brain region also has a key role to play when it comes to remembering positive and negative emotional experiences.

These types of emotional experiences are particularly well remembered by the brain, not least because it helps the survival of our species to be able to remember times when we were in danger and times when we prospered.

Scientists integrate human nerve cells into rat brains

Human brain tissue has been successfully transplanted into the brains of rats using a cutting-edge experimental procedure, say researchers. They envision the achievement as a promising new frontier in medical research.

Groups of living human nerve cells have become integrated into the brains of laboratory rats, creating hybrid brain circuits that can be activated through input from the rats’ senses, the scientists reported Wednesday.

Further, experiments have shown that the human tissue forms a two-way connection within the rat brain, also sending out signals that can potentially alter the rat’s behavior, the researchers said.

New Alzheimer’s Drug Appears to Actually Work, to Some Degree

Last year, the pharmaceutical company Biogen released a drug called Aduhelm. It was the first new Alzheimer’s drug approved by the FDA in almost 20 years, but its rollout was mired in controversy — vast swaths of experts decried its approval, claiming there simply wasn’t enough evidence to support its efficacy, while the Journal of American Medicine (JAMA) rejected Biogen’s key Aduhelm paper. Shortly thereafter, Medicare chose to limit coverage of the drug.

All that is to say that given last year’s Aduhelm spectacle, you’d be forgiven for doubting what appears to be a promising development in Biogen’s continued Alzheimer’s drug development. And that’s just what it announced with a collaborator, fellow pharmaceutical maker Eisai, on Tuesday. But that being said, initial data suggests that the new drug is actually proving quite successful in late-stage clinical trials — enough so that Biogen might have a redemption arc, after all.

That new drug, lecanemab, is an anti-amyloid medication. An amyloid is a type of protein, and a normal one for brains to produce. An overabundance of amyloids, however, is believed to be caused by a disruption in a healthy brain’s built-in protein disposal system, resulting in a plaque; although our understanding is still fuzzy, brains with Alzheimer’s are shown to have abnormal plaque levels, so the idea is that anti-amyloid lecenameb, administered intravenously, could scrub that plaque away.

New insights into how serotonin regulates behavior

Rates of anxiety and depression have been increasing around the world for decades, a trend that has been sharply exacerbated by the COVID-19 pandemic. New research led by the Boyce Thompson Institute’s Frank Schroeder could ultimately lead to new therapeutics to help relieve this global mental health burden.

First discovered in the 1930s, is a neurotransmitter produced in many animals that mediates myriad behaviors, such as feeding, sleep, mood and cognition. Drugs that alter are the main weapon to treat psychological conditions like anxiety and depression, as well as eating disorders.

As a simple model for neurobiology research, the microscopic roundworm Caenorhabditis elegans has been used extensively to study serotonin’s role in regulating and . For many years, researchers thought that serotonin was made in C. elegans by one specific molecular pathway, and that serotonin was then quickly degraded. Schroeder’s team and colleagues at Columbia University now demonstrated that both of those assumptions were not quite correct.

Caltech’s New Ultrafast Camera Captures Signals Traveling Through Nerve Cells

Reach out right now and touch anything around you. Whether it was the wood of your desk, a key on your keyboard, or the fur of your dog, you felt it the instant your finger contacted it.

Or did you?

In actuality, takes a bit of time for your brain to register the sensation from your fingertip. However, it does still happen extremely fast, with the touch signal traveling through your nerves at over 100 miles per hour. In fact, some nerve signals are even faster, approaching speeds of 300 miles per hour.